Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.67 |
| ▸ | STAT3 | P40763 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MIF | P14174 | 3/20 | 0.58 |
| ▸ | BCL2 | P10415 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869200 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22325167 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242290 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21333201 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20142514 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189563 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242552 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22326316 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21179283 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189483 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-11-14 | — | — | US | disclosed |
| EP-4448487-A1 | BCL6 DEGRADERS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-114390924-B | Compounds, compositions and methods for protein degradation | 达纳-法伯癌症研究公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3989967-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118420619-A | Compound for targeted protein degradation and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-08-02 | — | — | CN | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | disclosed |
| CN-114933589-B | Compound for inducing FGFR degradation based on CRBN ligand and preparation method and application thereof | 杭州医学院 | 2024-03-26 | — | — | CN | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023114460-A1 | BCL6 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220389023-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| CN-114933589-A | CRBN ligand-based FGFR degradation inducing compound and preparation method and application thereof | 杭州医学院 | 2022-08-23 | — | — | CN | disclosed |
| EP-3989967-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114390924-A | Compounds, compositions and methods for protein degradation | 达纳-法伯癌症研究公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2020264172-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264172-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389023-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PROTEIN DEGRADATION | SMARCA4, SMARCA2, SMARCE1 | CRBN 52/4885DDB1 86/4885HDAC3 720/4885 |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885DDB1 148/4885HDAC3 623/4885 |
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885DDB1 148/4885HDAC3 623/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | CRBN 302/4885DDB1 206/4885HDAC3 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.